Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib-Reference-Cited by-同舟云学术

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib

Published:2016-07-13 Issue:4 Volume:35 Page:711-718
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Kasamatsu Tetsuhiro¹,Saitoh Takayuki¹,Ino Rumi¹,Gotoh Nanami¹,Mitsui Takeki²,Shimizu Hiroaki²,Matsumoto Morio³,Sawamura Morio³,Yokohama Akihiko⁴,Handa Hiroshi²,Tsukamoto Norifumi⁵,Murakami Hirokazu¹

Affiliation:

1. Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan

2. Department of Medicine and Clinical Science; Gunma University; Maebashi Gunma Japan

3. National Hospital Organization; Nishigunma National Hospital; Shibukawa Gunma Japan

4. Blood Transfusion Service; Gunma University Hospital; Maebashi Gunma Japan

5. Oncology Center; Gunma University Hospital; Maebashi Gunma Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference35 articles.

1. Role of interleukin 6 in the growth of myeloma-derived cell lines;Barut;Leukemia Research,1992

2. Response patterns of purified myeloma cells to hematopoietic growth factors;Anderson;Blood,1989

3. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma;Bergui;J Exp Med,1989

4. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes;Rousset;Proceedings of the National Academy of Sciences of the United States of America,1992

5. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells;Péguet-Navarro;Eur J Immunol,1994

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing;Frontiers in Pharmacology;2024-09-13

2. Interleukin 10: Bridging the chasms in the immune landscape of multiple myeloma;International Review of Cell and Molecular Biology;2024

3. Serum levels of interleukin-10 and its receptor in the multiple myeloma type I patients;Journal of Research in Applied and Basic Medical Sciences;2023-10-01

4. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients;Pharmacological Reports;2021-06-05

5. The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma;Tzu Chi Medical Journal;2021